Evidence map›Paper›PMID 23299278›Full record

ArticleInternational journal of clinical oncology2014

Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study.

Naoto Kamiya, Hiroyoshi Suzuki, Takeshi Ueda, Naohide Sato, Hiroomi Nakatsu, Kazuo Mikami, Nobuo Sato, Kazushi Nomura, Koichiro Akakura, Tatsuya Okano and 5 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07503379 (Evaluation of the Efficacy and Safety of Darolutamide + ADT Combined With Low-dose Docetaxel in mHSPC), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07503379 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of the Efficacy and Safety of Darolutamide + ADT Combined With Low-dose Docetaxel in mHSPC: a Multi-center, Prospective, Single-arm Study

TypeinterventionalSponsorYonghong LiRan2026 to 2028Enrolled109ConditionsmHSPCArmsDarolutamide + ADT Combined with Low-dose Docetaxel
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 1 country.

Naoto KamiyaDepartment of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan, naoto.kamiya@med.toho-u.ac.jp.
Hiroyoshi Suzuki
Takeshi Ueda
Naohide Sato
Hiroomi Nakatsu
Kazuo Mikami
Nobuo Sato
Kazushi Nomura
Koichiro Akakura
Tatsuya Okano
Takemasa Ooki
Yukio Naya
Sho Ota
Motoyuki Masai
Tomohiko Ichikawa
Toho University · JPAsahi Hospital · JPChiba Aoba Municipal Hospital · JPChiba Cancer Center · JPChibaken Saiseikai Narashino Hospital · JPChiba University · JPFunabashi Central Hospital · JPFunabashi Municipal Medical Center · JPJapanese Red Cross Narita Hospital · JPNational Hospital Organization · JPTeikyo University Chiba Medical Center · JPTokyo Teishin Hospital · JPTomitahama Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to retrospectively investigate clinical outcomes by relative dose and dose intensity of docetaxel (DOC) as chemotherapy for Japanese patients with castration-resistant prostate cancer (CRPC).

methodsA total of 145 CRPC patients who received more than 4 courses of DOC chemotherapy at 14 hospitals between 2005 and 2011 were enrolled. Patients were divided into two groups--those receiving a higher or lower dose (mg/m(2)) or dose intensity (mg/m(2)/week). Differences between the groups regarding treatment outcomes and adverse events (AEs) were determined. Additionally, prognostic factors predictive of cancer-specific survival (CSS) in these patients were identified by both univariate and multivariate analysis.

resultsThe total patient group underwent a mean of 11.2 ± 7.4 DOC cycles, and the mean CSS after therapy was 15.6 ± 10.1 months. The higher-dose group had a better prostate-specific antigen (PSA) response than the lower-dose group. However, there was no significant difference between the groups in prognosis after DOC chemotherapy. Leukopenia and neutropenia were observed more frequently in the higher-dose group. Serum biomarkers (including PSA, lactate dehydrogenase and alkaline phosphatase), hemoglobin levels and presence of pain at initiation of chemotherapy, as well as the PSA nadir level on first-line hormone therapy, all were significant predictors of CSS.

conclusionsIn the Japanese population, relatively low-dose DOC chemotherapy had no deleterious effect on the CSS of CRPC patients, and a lower incidence of AEs occurred, in spite of a diminished PSA response compared with those receiving a higher dose.

Indexed as

Drug Resistance, NeoplasmAgedAged, 80 and overDocetaxelDose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsHumansJapanMaleMiddle AgedPrognosisProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantRetrospective StudiesTaxoidsTreatment OutcomeDocetaxelProstate-Specific AntigenTaxoids

Identifiers

PMID23299278
OpenAlexW2086025280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.